Kidney International
Fewer serious medical events with semaglutide in kidney trial
In the lowest kidney-function subgroup, serious medical events were reported in 56.4% receiving semaglutide versus 60.4% receiving placebo.In the lowest kidney-function subgroup, serious medical events were reported in 56.4% receiving semaglutide versus 60.4% receiving placebo.
Randomized trial · 3,533 peopleSemaglutide
Who was studied3,533 people with diabetes and chronic kidney disease, against placebo
What changedSerious medical events were lower with semaglutide: 56.4% versus 60.4% with placebo in the lowest kidney-function subgroup
The catchSafety monitoring collected only selected types of adverse events